Focus on Childhood and Adolescent Mental Health: Introduction. Medication and Diagnostic Issues
J Clin Psychiatry 2009;70(2):238-239
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
This section of Focus on Childhood and Adolescent Mental Health
presents timely information on the topics of polypharmacy, the
olanzapine safety profile, the role of conduct disorder in the development
of substance use disorder in adolescents with bipolar disorder, and autistic
spectrum disorder symptoms in a group of adolescent suspects of sex
Recent attention has focused on the use of polypharmacy for children
with psychiatric disorders. McIntyre and Jerrell examine the use of polypharmacy
for treatment of major depressive disorder in children and adolescents
using data obtained from the South Carolina Medicaid program
between the period January 1996 and December 2005. Consistent with
clinical expectations, they found that the likelihood of psychotropic
polypharmacy increased when there were comorbid psychiatric disorders,
with odds ratios ranging from 1.5 for 1 comorbid disorder to 9.8 for
6 comorbid disorders compared to an odds ratio of 0.4 for major depressive